A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

Cell Reports

Volumn 17, Issue 4, 2016, Pages 1193-1205

  Tzelepis, Konstantinos ^a   Koike Yusa, Hiroko ^a   De Braekeleer, Etienne ^a   Li, Yilong ^a   Metzakopian, Emmanouil ^a   Dovey, Oliver M ^a   Mupo, Annalisa ^a   Grinkevich, Vera ^a   Li, Meng ^a   Mazan, Milena ^a   Gozdecka, Malgorzata ^a   Ohnishi, Shuhei ^a   Cooper, Jonathan ^a   Patel, Miten ^a   McKerrell, Thomas ^a   Chen, Bin ^a   Domingues, Ana Filipa ^c   Gallipoli, Paolo ^c,d   Teichmann, Sarah ^a   Ponstingl, Hannes ^a   McDermott, Ultan ^a   Saez Rodriguez, Julio ^b,e   Huntly, Brian J P ^c,d   Iorio, Francesco ^b   Pina, Cristina ^c   Vassiliou, George S ^a,c,d   Yusa, Kosuke ^a   more..

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

acute myeloid leukemia; AML; CRISPR; genetic screen; genetic vulnerability; KAT2A; MB 3

Indexed keywords

CASPASE 9; CHECKPOINT KINASE 1; CRISPR ASSOCIATED PROTEIN; HISTONE DEACETYLASE 6; MICROSOMAL AMINOPEPTIDASE; TRANSCRIPTION FACTOR HOXA10; HISTONE ACETYLTRANSFERASE; KAT2A PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BCL2 GENE; CAENORHABDITIS ELEGANS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOT1L GENE; DOWN REGULATION; EMBRYONIC STEM CELL; EXPRESSION VECTOR; GENOTYPE; HUMAN; HUMAN CELL; KARYOTYPE; KAT2A GENE; LEUKEMIA CELL; MEN1 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; STREPTOCOCCUS PYOGENES; TUMOR GENE; ACUTE MYELOID LEUKEMIA; ADULT; ANTAGONISTS AND INHIBITORS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENETIC SCREENING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; REPRODUCIBILITY; TUMOR CELL LINE;

ADULT; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENETIC TESTING; HISTONE ACETYLTRANSFERASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; REPRODUCIBILITY OF RESULTS;

EID: 84994850910     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.09.079     Document Type: Article

References (48)

1. Bernt, K.M., Zhu, N., Sinha, A.U., Vempati, S., Faber, J., Krivtsov, A.V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20 (2011), 66–78.
2. Beroukhim, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J.S., Dobson, J., Urashima, M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463 (2010), 899–905.
3. Biel, M., Kretsovali, A., Karatzali, E., Papamatheakis, J., Giannis, A., Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew. Chem. Int. Ed. Engl. 43 (2004), 3974–3976.
4. Bignell, G.R., Greenman, C.D., Davies, H., Butler, A.P., Edkins, S., Andrews, J.M., Buck, G., Chen, L., Beare, D., Latimer, C., et al. Signatures of mutation and selection in the cancer genome. Nature 463 (2010), 893–898.
5. Boutros, M., Ahringer, J., The art and design of genetic screens: RNA interference. Nat. Rev. Genet. 9 (2008), 554–566.
6. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368 (2013), 2059–2074.
7. Chan, S.M., Thomas, D., Corces-Zimmerman, M.R., Xavy, S., Rastogi, S., Hong, W.J., Zhao, F., Medeiros, B.C., Tyvoll, D.A., Majeti, R., Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21 (2015), 178–184.
8. Chen, B., Gilbert, L.A., Cimini, B.A., Schnitzbauer, J., Zhang, W., Li, G.W., Park, J., Blackburn, E.H., Weissman, J.S., Qi, L.S., Huang, B., Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155 (2013), 1479–1491.
9. Cho, S.W., Kim, S., Kim, J.M., Kim, J.S., Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31 (2013), 230–232.
10. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., Zhang, F., Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
11. Dang, Y., Jia, G., Choi, J., Ma, H., Anaya, E., Ye, C., Shankar, P., Wu, H., Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. Genome Biol., 16, 2015, 280.
12. Daud, A.I., Ashworth, M.T., Strosberg, J., Goldman, J.W., Mendelson, D., Springett, G., Venook, A.P., Loechner, S., Rosen, L.S., Shanahan, F., et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J. Clin. Oncol. 33 (2015), 1060–1066.
13. Dawson, M.A., Prinjha, R.K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.I., Robson, S.C., Chung, C.W., Hopf, C., Savitski, M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478 (2011), 529–533.
14. Doench, J.G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E.W., Donovan, K.F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34 (2016), 184–191.
15. Döhner, H., Weisdorf, D.J., Bloomfield, C.D., Acute myeloid leukemia. N. Engl. J. Med. 373 (2015), 1136–1152.
16. Evans, J.S., Musser, E.A., Mengel, G.D., Forsblad, K.R., Hunter, J.H., Antitumor activity of 1-beta-D-arainofuranosylcytosine hydrochloride. Proc. Soc. Exp. Biol. Med. 106 (1961), 350–353.
17. Farboud, B., Meyer, B.J., Dramatic enhancement of genome editing by CRISPR/Cas9 through improved guide RNA design. Genetics 199 (2015), 959–971.
18. Ferrara, F., Schiffer, C.A., Acute myeloid leukaemia in adults. Lancet 381 (2013), 484–495.
19. Griffith, M., Griffith, O.L., Coffman, A.C., Weible, J.V., McMichael, J.F., Spies, N.C., Koval, J., Das, I., Callaway, M.B., Eldred, J.M., et al. DGIdb: mining the druggable genome. Nat. Methods 10 (2013), 1209–1210.
20. Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K.R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163 (2015), 1515–1526.
21. Holmlund, T., Lindberg, M.J., Grander, D., Wallberg, A.E., GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia 27 (2013), 578–585.
22. Hultquist, J.F., Lengyel, J.A., Refsland, E.W., LaRue, R.S., Lackey, L., Brown, W.L., Harris, R.S., Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85 (2011), 11220–11234.
23. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
24. Koike-Yusa, H., Li, Y., Tan, E.P., Velasco-Herrera, Mdel.C., Yusa, K., Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32 (2014), 267–273.
25. Krebs, A.R., Karmodiya, K., Lindahl-Allen, M., Struhl, K., Tora, L., SAGA and ATAC histone acetyl transferase complexes regulate distinct sets of genes and ATAC defines a class of p300-independent enhancers. Mol. Cell 44 (2011), 410–423.
26. Lee, B.H., Tothova, Z., Levine, R.L., Anderson, K., Buza-Vidas, N., Cullen, D.E., McDowell, E.P., Adelsperger, J., Fröhling, S., Huntly, B.J., et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 12 (2007), 367–380.
27. Li, W., Xu, H., Xiao, T., Cong, L., Love, M.I., Zhang, F., Irizarry, R.A., Liu, J.S., Brown, M., Liu, X.S., MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol., 15, 2014, 554.
28. Luo, J., Emanuele, M.J., Li, D., Creighton, C.J., Schlabach, M.R., Westbrook, T.F., Wong, K.K., Elledge, S.J., A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137 (2009), 835–848.
29. Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., Church, G.M., RNA-guided human genome engineering via Cas9. Science 339 (2013), 823–826.
30. Montes, R., Ayllón, V., Gutierrez-Aranda, I., Prat, I., Hernández-Lamas, M.C., Ponce, L., Bresolin, S., Te Kronnie, G., Greaves, M., Bueno, C., Menendez, P., Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood 117 (2011), 4746–4758.
31. Pan, R., Hogdal, L.J., Benito, J.M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D.J., Debose, L., Mu, H., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4 (2014), 362–375.
32. Pasini, D., Malatesta, M., Jung, H.R., Walfridsson, J., Willer, A., Olsson, L., Skotte, J., Wutz, A., Porse, B., Jensen, O.N., Helin, K., Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 38 (2010), 4958–4969.
33. Pettitt, S.J., Liang, Q., Rairdan, X.Y., Moran, J.L., Prosser, H.M., Beier, D.R., Lloyd, K.C., Bradley, A., Skarnes, W.C., Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nat. Methods 6 (2009), 493–495.
34. Schlabach, M.R., Luo, J., Solimini, N.L., Hu, G., Xu, Q., Li, M.Z., Zhao, Z., Smogorzewska, A., Sowa, M.E., Ang, X.L., et al. Cancer proliferation gene discovery through functional genomics. Science 319 (2008), 620–624.
35. Senyuk, V., Sinha, K.K., Chakraborty, S., Buonamici, S., Nucifora, G., P/CAF and GCN5 acetylate the AML1/MDS1/EVI1 fusion oncoprotein. Biochem. Biophys. Res. Commun. 307 (2003), 980–986.
36. Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., Zhang, F., Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343 (2014), 84–87.
37. Shi, J., Wang, E., Milazzo, J.P., Wang, Z., Kinney, J.B., Vakoc, C.R., Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat. Biotechnol. 33 (2015), 661–667.
38. Silva, J.M., Marran, K., Parker, J.S., Silva, J., Golding, M., Schlabach, M.R., Elledge, S.J., Hannon, G.J., Chang, K., Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319 (2008), 617–620.
39. Wang, L., Dent, S.Y., Functions of SAGA in development and disease. Epigenomics 6 (2014), 329–339.
40. Wang, T., Wei, J.J., Sabatini, D.M., Lander, E.S., Genetic screens in human cells using the CRISPR-Cas9 system. Science 343 (2014), 80–84.
41. Wang, T., Birsoy, K., Hughes, N.W., Krupczak, K.M., Post, Y., Wei, J.J., Lander, E.S., Sabatini, D.M., Identification and characterization of essential genes in the human genome. Science 350 (2015), 1096–1101.
42. Welch, J.S., Ley, T.J., Link, D.C., Miller, C.A., Larson, D.E., Koboldt, D.C., Wartman, L.D., Lamprecht, T.L., Liu, F., Xia, J., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150 (2012), 264–278.
43. Wilson, N.K., Schoenfelder, S., Hannah, R., Sánchez Castillo, M., Schütte, J., Ladopoulos, V., Mitchelmore, J., Goode, D.K., Calero-Nieto, F.J., Moignard, V., et al. Integrated genome-scale analysis of the transcriptional regulatory landscape in a blood stem/progenitor cell model. Blood 127 (2016), e12–e23.
44. Zabludoff, S.D., Deng, C., Grondine, M.R., Sheehy, A.M., Ashwell, S., Caleb, B.L., Green, S., Haye, H.R., Horn, C.L., Janetka, J.W., et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 7 (2008), 2955–2966.
45. Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G., Tabak, B., Lawrence, M.S., Zhsng, C.Z., Wala, J., Mermel, C.H., et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45 (2013), 1134–1140.
46. Zhang, Y., Wong, C.H., Birnbaum, R.Y., Li, G., Favaro, R., Ngan, C.Y., Lim, J., Tai, E., Poh, H.M., Wong, E., et al. Chromatin connectivity maps reveal dynamic promoter-enhancer long-range associations. Nature 504 (2013), 306–310.
47. Zhou, Y., Zhu, S., Cai, C., Yuan, P., Li, C., Huang, Y., Wei, W., High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509 (2014), 487–491.
48. Zuber, J., Shi, J., Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478 (2011), 524–528.